Analyst consensus

The consensus estimates are collected by the company and based on the estimates of brokerage firms covering GlaxoSmithKline. Please ensure you have read and acknowledged the disclaimer prior to reviewing the information provided.

FY2019-2023 figures are as at 27/11/2019

All figures shown are on an Adjusted basis unless stated. 
 

Please select...
£m (unless stated) 2019 2020 2021 2022 2023 2019-2023 n=
Turnover 33,892 35,528 36,793 38,283 39,830 13
Cost of sales (10,007) (10,387) (10,750) (11,097) (11,477) 13
Selling, general and administration (10,542) (11,058) (11,264) (11,538) (11,817) 13
Research and Development (4,429) (4,803) (5,002) (5,173) (5,340) 13
Royalty income 349 354 358 351 347 13
Operating profit 9,263 9,634 10,135 10,825 11,544 13
Net finance costs (858) (874) (821) (788) (749) 13
Associates 71 19 19 19 19 13
Profit before tax 8,475 8,779 9,333 10,057 10,814 13
Taxation (1,441) (1,612) (1,755) (1,902) (2,047) 13
Profit after tax  7,034 7,167 7,579 8,154 8,767 13
Minority interests (847) (1,189) (1,264) (1,340) (1,394) 13
Profit attributable to shareholders 6,187 5,978 6,315 6,814 7,373 13
WANS (m) 4,941 4,958 4,979 5,000 5,020 13
Earnings per share (p) 125.2 120.6 126.8 136.3 146.9 13
Dividend per share (p) 80.0 80.0 80.1 80.7 81.9 12
Free Cash Flow 3,305 4,726 5,349 5,984 6,612 10
Net Debt (25,665) (23,475) (22,302) (20,671) (18,340) 12

The firms included are: Bank of America Merrill Lynch, Barclays, Citi, Credit Suisse, Deutsche Bank, Exane, Guggenheim Securities, Jefferies, JP Morgan, Morgan Stanley, Redburn, UBS, Wolfe Research

Turnover £m 2019 2020 2021 2022 2023 2019-2023 n=
Anoro 521 561 594 617 636 13
Arnuity 47 50 52 53 54 13
Incruse 263 284 302 320 335 13
Relvar/Breo 988 987 1,008 1,024 1,036 13
Trelegy 514 785 1,029 1,227 1,385 13
Ellipta portfolio 2,333 2,666 2,985 3,241 3,445 13
Nucala 765 897 993 1,071 1,128 13
Total Respiratory 3,098 3,563 3,978 4,313 4,573 13
             
Tivicay 1,669 1,618 1,576 1,530 1,484 11
Triumeq 2,554 2,351 2,207 2,093 1,992 11
Juluca 371 526 624 696 744 12
Dovato 54 253 469 684 841 12
Dolutegravir based regimens 4,647 4,741 4,852 4,967 5,011 13
Cabotegravir +/- rilpivirine - 58 183 316 458 13
fostemsavir - 35 97 150 205 11
Epzicom/Kivexa 79 60 49 41 36 13
HIV 4,881 5,025 5,276 5,541 5,759 13
             
Benylsta 617 708 781 840 859 13
             
Zejula 242 391 548 718 870 13
             
Advair (US) 495 254 182 151 130 12
Seretide (ex US) 1,225 1,077 962 880 811 12
Seretide/Advair 1,720 1,330 1,144 1,030 942 13
Flixotide/Flovent 578 531 497 468 442 13
Ventolin 961 762 705 678 656 13
Avamys/Veramyst 326 335 340 340 309 13
Established Respiratory 3,861 3,225 2,947 2,770 2,595 13
Other Established Pharmaceuticals 4,938 4,671 4,442 4,243 4,051 13
Established Pharmaceuticals 8,799 7,897 7,389 7,013 6,646 13
             
belantamab mafodotin (GSK'916 BCMA) - 74 220 392 590 13
dostarlimab - 18 56 100 153 9
daprodustat - - 18 78 167 12
             
Pharmaceuticals 17,639 17,671 18,263 19,072 19,856 13


The firms included are: Bank of America Merrill Lynch, Barclays, Citi, Credit Suisse, Deutsche Bank, Exane, Guggenheim Securities, Jefferies, JP Morgan, Morgan Stanley, Redburn, UBS, Wolfe Research

Turnover £m 2019 2020 2021 2022 2023 2019-2023 n=
Bexsero 694 763 822 867 902 13
Menveo 249 256 264 272 280 13
Fluarix/Flulaval 574 587 605 622 639 13
Shingrix 1,743 2,029 2,265 2,482 2,786 13
Boostrix 593 605 619 630 640 13
Cervarix 98 96 97 97 98 13
Hepatitis 879 893 911 929 944 13
Infanrix, Pediarix 746 734 737 743 747 13
Rotarix 550 560 571 582 593 13
Synflorix 445 444 443 439 433 13
Vaccines 7,162 7,486 7,868 8,217 8,639 13


The firms included are: Bank of America Merrill Lynch, Barclays, Citi, Credit Suisse, Deutsche Bank, Exane, Guggenheim Securities, Jefferies, JP Morgan, Morgan Stanley, Redburn, UBS, Wolfe Research

Back to top